Convergent Genomics Home

About Us
Our Products
Our Science
Clinical Expertise
Newsroom
Contact

About Us
Our Products
Our Science
Clinical Expertise
Newsroom
Contact

AUA I 2022

Jul 28, 2023

Urine comprehensive genomic profiling predicts recurrence in patients with non-muscle invasive bladder cancer treated with intravesical therapy carcinoma

Contact us
425 Eccles Ave, South San Francisco, CA 94080
info@convergentgenomics.com
415-839-0077







Financial Conflict of
Interest Policy

CA: CDF-90003755 | CLIA # 05D2220749 | CAP Accredited # 9512563

The UroAmp test has been developed, its performance characteristics determined, and validated by our CLIA-certified and CAP-accredited laboratory, which performs the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.